CA1134273A - Benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts - Google Patents
Benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid saltsInfo
- Publication number
- CA1134273A CA1134273A CA396,307A CA396307A CA1134273A CA 1134273 A CA1134273 A CA 1134273A CA 396307 A CA396307 A CA 396307A CA 1134273 A CA1134273 A CA 1134273A
- Authority
- CA
- Canada
- Prior art keywords
- acid
- benzene
- formula
- hydrochloride
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
Novel pharmaceutical compositions useful as a mucolytic agent in an animal body suffering from lung congestion comprising a benzene carbothioic acid, 2-aminoalkyl ester acid salt having the formula:
Novel pharmaceutical compositions useful as a mucolytic agent in an animal body suffering from lung congestion comprising a benzene carbothioic acid, 2-aminoalkyl ester acid salt having the formula:
Description
~13~'3 The present inyention is concerned with certain benzene carbothioic acid-2~aminoalkylester acid salts useful in combatting and controlling mucus build-up in an animal exhibiting lung congestion and compositions for use as mucolytic agents.
This application is divided from applicant's co-pending application Serial No. 333,424 filed on August 9, 1979 which is directed to certain novel compounds selected from a compound selected from substituted benzene and thiophenecarbothioic acid,
This application is divided from applicant's co-pending application Serial No. 333,424 filed on August 9, 1979 which is directed to certain novel compounds selected from a compound selected from substituted benzene and thiophenecarbothioic acid,
2-aminoalkyl ester acid salts having the formula:
ro ¦R-C-S(CH2)nNH3 ¦ X
~herein R is 2-thiophene, benzene substituted by one to three radicals which may be the same or different, selected from halogen, lower alkyl, lower alkoxy, carboxy or trifluoromethyl, X is chlorine or bromine radical, and n is 2 or 3, these novel compounds also having been found ~o exhibit mucolytic activity.
The prior art discloses synthesis of benzene carbothioic acid-2-aminoethylester hydrochloride, W. O. Foye et al, J. Pharm.
Sci. 51 (2), 168-~1 (1962) but there is no disclosure of mucolytic activity. Substitution on benzene has not been disclosed. The prior art discloses certain mucolytic agents such as N-acetyl-cysteine having a free sulfhydryl group, which group compounds of the present invention do not have. A. L. Sheffner, Ann. N.Y.
Acad. Sci. 106, 298-310 (1963) established the use of gastric mucin mucoprotein as a test media in development of N-acetyl-L-cysteine as a mucolytic agent in the treatment of lung disease.
According to the present invention there is provided - 1 - ~ ., :. ~- ; : - : . :- . - , : ~ , ,, . -~3~ 7~3 a pharmaceutical compos~tion useful as a mucolytic agent in an animal body sufferin~ from lung congestion which comprises a pharmaceutically active amount of a compound of the formula l _ _ IR-C-S(CH2)nNH3 wherein; R is benzene, X is chlorine or bromine radical, and n is 2 or 3, which is in admixture with a pharmaceutically accept-able diluent or carrier.
The compositions have mucolytic activity and are useful in dissolving and diluting mucus in warm-blooded animals exhibiting or suffering from lung congestion.
The present invention, together with those novel com-pounds of the aforementioned application Serial No. 333,424, will now be further described.
The novel and known compounds described hereinafter and represented by the Formula I
~- 0 +I
( 2)n 3 ~
Formula I
wherein; R is 2-thiophene, benzene or benzene substituted by one to three radicals which are selected from halogen lower-alkyl, lower-alkoxy, carboxy or trifluoromethyl and may be the same or ~0 different and in various positions relative to one another on the ring. X is a chlorine or bromine radical and n is 2 or 3, have been shown by a modification of the method of S. J. Carne et al, ~:~l3~
J. Phys. 242, 116 (1~74) as described he~einbelow ~hown to have mucolytic activity in antmals.
Compounds for which mucolytic activity was found to be of the same order of magnitude as N-acetyl-L-cysteine on rat stomach mucus are the preferred compounds ~hich are:
1) Benzenecarbothioic acid, 2-aminoethyl ester, monohydro-chloride, 2) 4-Chlorobenzenecarbothioic acid, 2-aminoethyl ester, monohydrochloride,
ro ¦R-C-S(CH2)nNH3 ¦ X
~herein R is 2-thiophene, benzene substituted by one to three radicals which may be the same or different, selected from halogen, lower alkyl, lower alkoxy, carboxy or trifluoromethyl, X is chlorine or bromine radical, and n is 2 or 3, these novel compounds also having been found ~o exhibit mucolytic activity.
The prior art discloses synthesis of benzene carbothioic acid-2-aminoethylester hydrochloride, W. O. Foye et al, J. Pharm.
Sci. 51 (2), 168-~1 (1962) but there is no disclosure of mucolytic activity. Substitution on benzene has not been disclosed. The prior art discloses certain mucolytic agents such as N-acetyl-cysteine having a free sulfhydryl group, which group compounds of the present invention do not have. A. L. Sheffner, Ann. N.Y.
Acad. Sci. 106, 298-310 (1963) established the use of gastric mucin mucoprotein as a test media in development of N-acetyl-L-cysteine as a mucolytic agent in the treatment of lung disease.
According to the present invention there is provided - 1 - ~ ., :. ~- ; : - : . :- . - , : ~ , ,, . -~3~ 7~3 a pharmaceutical compos~tion useful as a mucolytic agent in an animal body sufferin~ from lung congestion which comprises a pharmaceutically active amount of a compound of the formula l _ _ IR-C-S(CH2)nNH3 wherein; R is benzene, X is chlorine or bromine radical, and n is 2 or 3, which is in admixture with a pharmaceutically accept-able diluent or carrier.
The compositions have mucolytic activity and are useful in dissolving and diluting mucus in warm-blooded animals exhibiting or suffering from lung congestion.
The present invention, together with those novel com-pounds of the aforementioned application Serial No. 333,424, will now be further described.
The novel and known compounds described hereinafter and represented by the Formula I
~- 0 +I
( 2)n 3 ~
Formula I
wherein; R is 2-thiophene, benzene or benzene substituted by one to three radicals which are selected from halogen lower-alkyl, lower-alkoxy, carboxy or trifluoromethyl and may be the same or ~0 different and in various positions relative to one another on the ring. X is a chlorine or bromine radical and n is 2 or 3, have been shown by a modification of the method of S. J. Carne et al, ~:~l3~
J. Phys. 242, 116 (1~74) as described he~einbelow ~hown to have mucolytic activity in antmals.
Compounds for which mucolytic activity was found to be of the same order of magnitude as N-acetyl-L-cysteine on rat stomach mucus are the preferred compounds ~hich are:
1) Benzenecarbothioic acid, 2-aminoethyl ester, monohydro-chloride, 2) 4-Chlorobenzenecarbothioic acid, 2-aminoethyl ester, monohydrochloride,
3) 4-Methylbenzenecarbothioic acid, 2-aminoethyl ester, monohydrochloride,
4) 4-Methoxybenzenecarbothioic acid, 2-aminoethyl ester, monohydrochloride,
5) 2-Thiophenecarbothioic acid, 2-aminoethyl ester, monohydro-chloride.
The method used to establish mucolytic activity in the compounds o formula I is as follows.
Female Sprague-Dawley (Charles River Labs) 120-180 g rats are fasted 16 hours on wire, housed two animals per cage.
~0 To minimize coprophogia, the lights are left on during the fast.
Two cc of water are given orally to each rat to minimi~e internal debris. Thirty minutes later the rats are sacrificed by cervical dislocation. The stomachs are removed, trimmed of excess tissue and the epithelial portion discarded. The glandular portion is cut sufficiently along the greater and lesser curvature to cause eversion of the stomach be~ore placing it in the drug solution. Stomachs with a fecal odor or containing visible fecal .
..
~:: , ; : : ~ . .. :
. . : : ,.
:, . " .:: : : .::
- . :, : : :
matter a~e d~sc~rdede ~to~achs are ~lace~ n lQ cc of solution (water or 5Q% PE~ 300~H2a dependin~ on solu~lity) containing 2.5 mg test compound/ml for 40 minutes. After drug treatment the stomachs are placed in 10 cc Alcian blue solution (Solution 1) for 90 minutes where the dye complexes with the stomach mucus.
After two successive lO~minute washes in 10 cc of 0.25 M. sucrose solution (Solution 2), the stomachs are placed in 10 cc 0.5 MgC12 solution (Solution 3) for one hour to remove the complexed dye.
The MgC12 supernatant is shaken with 10 cc diethyl ether in a 60 cc separatory ~unnel to remove lipids. The aqueous phase is drained into a Spectronic 20 tube and the percent transmission is read at 605 m,u in a Spectronic 20 spectrophotometer. The per-cent transmission is converted to ~g/ml of Alcian Blue from a standard curve. (P. Whiteman, Biochem. J. 131, 351-57 (1973).
Each drug or drug vehicle (control) is tested on three stomachs.
Mean differences between treated and control values are expressed as percentages.
Solution l-Alcian Blue, 0.05% w/v (1 liter) 54.8 g. sucrose (0.15 M)
The method used to establish mucolytic activity in the compounds o formula I is as follows.
Female Sprague-Dawley (Charles River Labs) 120-180 g rats are fasted 16 hours on wire, housed two animals per cage.
~0 To minimize coprophogia, the lights are left on during the fast.
Two cc of water are given orally to each rat to minimi~e internal debris. Thirty minutes later the rats are sacrificed by cervical dislocation. The stomachs are removed, trimmed of excess tissue and the epithelial portion discarded. The glandular portion is cut sufficiently along the greater and lesser curvature to cause eversion of the stomach be~ore placing it in the drug solution. Stomachs with a fecal odor or containing visible fecal .
..
~:: , ; : : ~ . .. :
. . : : ,.
:, . " .:: : : .::
- . :, : : :
matter a~e d~sc~rdede ~to~achs are ~lace~ n lQ cc of solution (water or 5Q% PE~ 300~H2a dependin~ on solu~lity) containing 2.5 mg test compound/ml for 40 minutes. After drug treatment the stomachs are placed in 10 cc Alcian blue solution (Solution 1) for 90 minutes where the dye complexes with the stomach mucus.
After two successive lO~minute washes in 10 cc of 0.25 M. sucrose solution (Solution 2), the stomachs are placed in 10 cc 0.5 MgC12 solution (Solution 3) for one hour to remove the complexed dye.
The MgC12 supernatant is shaken with 10 cc diethyl ether in a 60 cc separatory ~unnel to remove lipids. The aqueous phase is drained into a Spectronic 20 tube and the percent transmission is read at 605 m,u in a Spectronic 20 spectrophotometer. The per-cent transmission is converted to ~g/ml of Alcian Blue from a standard curve. (P. Whiteman, Biochem. J. 131, 351-57 (1973).
Each drug or drug vehicle (control) is tested on three stomachs.
Mean differences between treated and control values are expressed as percentages.
Solution l-Alcian Blue, 0.05% w/v (1 liter) 54.8 g. sucrose (0.15 M)
6.8 g. sodium acetate 900 cc. deionized water ~0 Dissolve with a magnetic stirrer and adjust to pH 5.8. Add 500 mg.
Alcian Blue 8 GN (Matheson Coleman & Bell # 8E13). Fill to one liter in a volumetric flask. Refrigerate. Use only for one week.
Solu*ion 2-Sucrose, 0.25 M (1 liter) Add 85.6 g of sucrose to one liter volumetric flask, Fill to volume with deionized water. Use only for one week.
~.~3~
Solution 3-Magnesium Chloride, 0.5 M (1 liter) Add 101.7 g Mg C12.6H20 A.C.S. to a one liter volumetric flask.
Fill to volume with deionized water.
It is ~herefore an object of the present invention to provide certain novel carbothioic acid, 2-aminoalkylester acid salts having mucolytic activity in a warm-blooded animal.
A further object is to provide a method of using benzene and substituted benzene and 2-thiophene carbothioic acid-2-aminoalkylester acid salts as mucolytic agents to combat mucus build-up in a warm-blooded animal suffering from lung congestion.
A still further object is to provide pharmaceutical compositions containing the compounds useful for controlling congestion due to mucus in a warm-blooded animal body.
Additional objects and advantages of the present in-vention will be apparent to one skilled in the art and still others will become apparent from the following description of the best mode of carrying out the present invention and from the appended claims.
In the definition of the symbols and in Formula I given above, and where they appear elsewhere throughout the claims and specification hereof, the terms have the following significance.
"Benzene substituted by one to 3 radicals" as used herein shall mean a phenyl radical which is substituted by one to 3 radi-cals selected from the group as hereinabove defined under the de-finition of R and these substituents can be in various available positions of the phenyl nucleus and when more thanoneisubstituent is present,may be the same or di~ferent and may be in various position combinations relative to each other. The lower-alkyl and lower-alkoxy substituents each have preferably from one to four carbon atoms which can be arranged as straight or branched chains.
Examples of the preferred substituents are methyl, ethyl, propyl, butyl, fluoro, bromo, chloro, iodo, methoxy, ethoxy, butoxy, carboxy and trifluoromethyl radicals.
METHOD OF PREPARATION
The benzene and substituted benzene and thiophenecarbo-thioic acid, 2-aminoalkylester acid salts are prepared by procedures known for preparing the benzene derivatives as represented by the following equation:
o R-C-X + HS(CH2)nNH2-HX~ ~ +
¦R-C-S (CH2) nNH3 ¦ X
wherein R, n and X are as defined hereinabove.
Generally, the reactants are mixed and heated over a steam jet until a mass of cyrstals are formed. The mass of cyrstals is then broken up, triturated with ligroine and recrystallized from anhydrous ethanol.
The following examples of preparation of compounds are only intended to illustrate the present invention and are not to be construed as limiti~g the invention in any respect.
Example 1 Benzenecarbothioic Acid, 2-Aminoethylester, Mono-~.
A mixture of benzoyl chloride, 15 ml. (ca 0.13 mole) and ~3~
2-aminoethanethiol hydrochloride, 4.54 g. (0.04 mole) was heated (protected from moisture) over a steam jet for 2 hours. Slight cooling produced a mass of crystals. After trituration with 60-110C. ligroine filtration and drying, the crystals melted at 177-180C. Se~eral recrystallizations from anhydrous ethanol produced a colorless solid which melted at 178.5-179.5C. Nuclear Magnetic Resonance (NMR), Mass Spectrophotometer (MS) and Infra Red (I~) analyses all supported structure of the title compound in accordance with Formula I. Yield was 5.1 g. (59.1~).
Analysis: Calculated for C8C12ClNOS: C,49.65; H,5.55; N, 6.43 Found : C,49.58; Ht5.59; N, 6.49 Example 2 4-Chlorobenzenecarbothioic Acid, 2-Aminoethyl Ester, Monohydrochloride.
A mixture of freshly distilled p-chlorobenzoyl chloride, 60 ml. (0.47 mole) and 2-aminoethanethiol hydrochloride, 18.18 g. (0.16 mole) was heated (protected from moisture) over a steam jet for 2 hours. A solid crystalline mass formed as the reaction went to completion. After careful trituration with ~0 warm 60-110C. ligroine, crystals were separated by filtration while washing with ligroine. After two recrystallizations from anhydrous ethanol, the product, 39.0 g. (96.5%), melted at 208-209.5C. NMR, MS and IR analyses all supported structure of the title compound in accordance with Formula I.
Analysis: Calculated for C~HllC12SNO: C,42.87i H,4.40; N,5.55 Found : C,42.79; H,4.43; N,5.59 ~ 7 -- ,, , , . ., :
. . . ~ . , . : . .. ~ . . ..
. , - :, ; ,, . . . :.
, . .. .~ .. . .
~34~ 3 Example 3 4-Methylbenzenecarbothioic Acid, 2-Aminoethyl Ester, Monohydrochloride.
A mixture o freshly distilled p-toluoyl chloride, b.p.
122C./32 mm, Hg., 30 ml. (ca 0.18 moles) and 2-aminoethanethiol hydrochloride, 9.68 g. (0.085 moles) was heated (protected from moisture) over a steam jet for 2.25 hours. A solid crystalline mass formed on completion of the reaction. The mass was crushed and careully triturated with warm 60-110C. ligroine and crystals were separated by iltration and washed with warm ligroine. After two recrystallizations from anhydrous ethanol, the product, 19.07 g. (97%), melted at 206.5-208C. NMR, MS and IR analyses all supported the structure of the title compound in accordance with Formula I.
Analysis: Calculated for CloH14NOClS: C,51.83; H,6.09; N,6.04 Found : C,51.57; H,6.06; N.6.11 Example 4 4-~ethoxybenzenecarbothioic Acid, 2-Aminoethyl Ester, Monohydrochloride.
~0 A mixture of p-anisoyl chloride, 23 ml. (ca 0.135 mole) and 2-aminoethanethiol hydrochloride, 7.4 g. (0.065 mole) was heated (protected ~rom moisture) over a steam jet for about 2 hours.
The resultant crystalline mass was crushed and carefully triturated with warm 60-110C. ligroine and crystals were separated by filtration and washed with warm ligroine. Ater two recrystal-lizations from anhydrous ethanol, the productl 14.6 g. (90.6%) -melted at 191.5~1q3~C. NMR, MS and IR analyses all supported the s~ructure of the title compound in accordance with Formula I.
Analysis: Calculated for C10~14ClN02S: C,48.48; H,5.69; N,5.65 Found : C,48.42; H,5.73; N,5.66 Example_5 When in the procedure of Example 1, benzoyl chloride is replaced by equal molar amounts of 3,4,5-trimethoxybenzoyl chloride, 4-fluorobenzoyl chloride, 3-trifluoromethylbenzoyl chloride, 3,4-dichlorobenzoyl chloride, 3,4-dimethylbenzoyl chloride, and 4-carboxybenzoyl chloride there are obtained 3,4,5-trimethoxybenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, 4-flurorobenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, 3-trifluoromethylbenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, ~0 3,4-dichlorobenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, 3,4-dimethylbenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, and 4-carboxybenzenecarbothioic acid, 2-aminoethyl ester hydrochloride.
Example~6 ~ hen in the procedure of Example 1, 2-aminoethanethiol ~.~,3~f~7~3 hydrochloride is replaced by equal molar amounts of 3-amino-propanethiol hydrochloride, there is obtained benzenecarbothioic acid-3-aminopropylester hydrochloride.
Example 7 When in the procedure of Example 1, 2-aminoethanethiol h~drochloride is replaced by equal molar amounts of 3~amino-propanethiol hydrochloride and benzoyl chloride is replaced by p-chlorobenzoyl chloride, p-toluoyl chloride, or p-anisoyl chloride there are obtained 4-chlorobenzenecarbothioic acid, 3-aminopropyl ester hydrochloride, 4-methylbenzenecarbothioic acid, 3-aminopropyl ester hydrochloride, and 4-methoxybenzenecarbothioic acid, 3-aminopropyl ester hydrochloride.
Example 8 2-Thiophenecarbothioic Acid, 2-Aminoethyl Ester, 2a Hydrochloride.
A mixture of freshly distilled 2-thiophenecarbonyl chloride, 15.8 g. (0.108 mole) and 2-aminoethanethiol hydrochloride 11.3 g. (0.1 mole) was heated (protected from mois~ure) over a steam jet for 6 hours. The resulting solid crystalline mass was crushed and triturated with warm 60-110C. ligroine and filtered to collect the crystals. After two recrystallizations from anh~drous ethanol, the product, 8.41 g. (75.5%) melted at 195-196.5C. NMR, MS and IR all supported the structure of the title compound in accordance with Formula I.
Analysis: Calculated for C7HloClNOS2: C,37.58; H,4.51; N,6.26 Found : C,37.68; H,4.50; N,6.30 Example 9 When in the procedure of Example 8, 2-aminoethanethiol hydrochloride is replaced by equal molar amounts of 3-amino propanethiol hydrochloride, there is obtained thiophenecarbothioic acid, 3-aminopropyl ester hydrochloride.
The pharmaceutical compositions of this invention comprise benzenecarbothioic aoid, 2-aminoethyl ester acid salts in an amount sufficient to provide efective action against lung congestion in warm-blooded animal subjects when applied topically as an inhalant.
The compounds of Formula I are administered in an amount sufficient to induce liquefaction of mucus in the respiratory tract o warm-blooded animals in need thereo. Intratracheal administration of the compounds of Formula I is effected by various inhalation or instillation means such as nose drops, sprays, aerosols and the like. Another suitable means of administration ~0 is by insufflation of micronized particle or ultra-fine powder utilizing only the energy of the inspiratory action or by use of aerosol propellants. Solutions or suspensions having about 0.5 to 5% weight of the mucolytic agent of Formula I are suitable for application by spraying with an atomizer, nebulizer, aerosol and the like.
~ t will be readily apparent to those skilled in the medical art that the correct dosage of a compound to be employed -- 11 -- ..
Alcian Blue 8 GN (Matheson Coleman & Bell # 8E13). Fill to one liter in a volumetric flask. Refrigerate. Use only for one week.
Solu*ion 2-Sucrose, 0.25 M (1 liter) Add 85.6 g of sucrose to one liter volumetric flask, Fill to volume with deionized water. Use only for one week.
~.~3~
Solution 3-Magnesium Chloride, 0.5 M (1 liter) Add 101.7 g Mg C12.6H20 A.C.S. to a one liter volumetric flask.
Fill to volume with deionized water.
It is ~herefore an object of the present invention to provide certain novel carbothioic acid, 2-aminoalkylester acid salts having mucolytic activity in a warm-blooded animal.
A further object is to provide a method of using benzene and substituted benzene and 2-thiophene carbothioic acid-2-aminoalkylester acid salts as mucolytic agents to combat mucus build-up in a warm-blooded animal suffering from lung congestion.
A still further object is to provide pharmaceutical compositions containing the compounds useful for controlling congestion due to mucus in a warm-blooded animal body.
Additional objects and advantages of the present in-vention will be apparent to one skilled in the art and still others will become apparent from the following description of the best mode of carrying out the present invention and from the appended claims.
In the definition of the symbols and in Formula I given above, and where they appear elsewhere throughout the claims and specification hereof, the terms have the following significance.
"Benzene substituted by one to 3 radicals" as used herein shall mean a phenyl radical which is substituted by one to 3 radi-cals selected from the group as hereinabove defined under the de-finition of R and these substituents can be in various available positions of the phenyl nucleus and when more thanoneisubstituent is present,may be the same or di~ferent and may be in various position combinations relative to each other. The lower-alkyl and lower-alkoxy substituents each have preferably from one to four carbon atoms which can be arranged as straight or branched chains.
Examples of the preferred substituents are methyl, ethyl, propyl, butyl, fluoro, bromo, chloro, iodo, methoxy, ethoxy, butoxy, carboxy and trifluoromethyl radicals.
METHOD OF PREPARATION
The benzene and substituted benzene and thiophenecarbo-thioic acid, 2-aminoalkylester acid salts are prepared by procedures known for preparing the benzene derivatives as represented by the following equation:
o R-C-X + HS(CH2)nNH2-HX~ ~ +
¦R-C-S (CH2) nNH3 ¦ X
wherein R, n and X are as defined hereinabove.
Generally, the reactants are mixed and heated over a steam jet until a mass of cyrstals are formed. The mass of cyrstals is then broken up, triturated with ligroine and recrystallized from anhydrous ethanol.
The following examples of preparation of compounds are only intended to illustrate the present invention and are not to be construed as limiti~g the invention in any respect.
Example 1 Benzenecarbothioic Acid, 2-Aminoethylester, Mono-~.
A mixture of benzoyl chloride, 15 ml. (ca 0.13 mole) and ~3~
2-aminoethanethiol hydrochloride, 4.54 g. (0.04 mole) was heated (protected from moisture) over a steam jet for 2 hours. Slight cooling produced a mass of crystals. After trituration with 60-110C. ligroine filtration and drying, the crystals melted at 177-180C. Se~eral recrystallizations from anhydrous ethanol produced a colorless solid which melted at 178.5-179.5C. Nuclear Magnetic Resonance (NMR), Mass Spectrophotometer (MS) and Infra Red (I~) analyses all supported structure of the title compound in accordance with Formula I. Yield was 5.1 g. (59.1~).
Analysis: Calculated for C8C12ClNOS: C,49.65; H,5.55; N, 6.43 Found : C,49.58; Ht5.59; N, 6.49 Example 2 4-Chlorobenzenecarbothioic Acid, 2-Aminoethyl Ester, Monohydrochloride.
A mixture of freshly distilled p-chlorobenzoyl chloride, 60 ml. (0.47 mole) and 2-aminoethanethiol hydrochloride, 18.18 g. (0.16 mole) was heated (protected from moisture) over a steam jet for 2 hours. A solid crystalline mass formed as the reaction went to completion. After careful trituration with ~0 warm 60-110C. ligroine, crystals were separated by filtration while washing with ligroine. After two recrystallizations from anhydrous ethanol, the product, 39.0 g. (96.5%), melted at 208-209.5C. NMR, MS and IR analyses all supported structure of the title compound in accordance with Formula I.
Analysis: Calculated for C~HllC12SNO: C,42.87i H,4.40; N,5.55 Found : C,42.79; H,4.43; N,5.59 ~ 7 -- ,, , , . ., :
. . . ~ . , . : . .. ~ . . ..
. , - :, ; ,, . . . :.
, . .. .~ .. . .
~34~ 3 Example 3 4-Methylbenzenecarbothioic Acid, 2-Aminoethyl Ester, Monohydrochloride.
A mixture o freshly distilled p-toluoyl chloride, b.p.
122C./32 mm, Hg., 30 ml. (ca 0.18 moles) and 2-aminoethanethiol hydrochloride, 9.68 g. (0.085 moles) was heated (protected from moisture) over a steam jet for 2.25 hours. A solid crystalline mass formed on completion of the reaction. The mass was crushed and careully triturated with warm 60-110C. ligroine and crystals were separated by iltration and washed with warm ligroine. After two recrystallizations from anhydrous ethanol, the product, 19.07 g. (97%), melted at 206.5-208C. NMR, MS and IR analyses all supported the structure of the title compound in accordance with Formula I.
Analysis: Calculated for CloH14NOClS: C,51.83; H,6.09; N,6.04 Found : C,51.57; H,6.06; N.6.11 Example 4 4-~ethoxybenzenecarbothioic Acid, 2-Aminoethyl Ester, Monohydrochloride.
~0 A mixture of p-anisoyl chloride, 23 ml. (ca 0.135 mole) and 2-aminoethanethiol hydrochloride, 7.4 g. (0.065 mole) was heated (protected ~rom moisture) over a steam jet for about 2 hours.
The resultant crystalline mass was crushed and carefully triturated with warm 60-110C. ligroine and crystals were separated by filtration and washed with warm ligroine. Ater two recrystal-lizations from anhydrous ethanol, the productl 14.6 g. (90.6%) -melted at 191.5~1q3~C. NMR, MS and IR analyses all supported the s~ructure of the title compound in accordance with Formula I.
Analysis: Calculated for C10~14ClN02S: C,48.48; H,5.69; N,5.65 Found : C,48.42; H,5.73; N,5.66 Example_5 When in the procedure of Example 1, benzoyl chloride is replaced by equal molar amounts of 3,4,5-trimethoxybenzoyl chloride, 4-fluorobenzoyl chloride, 3-trifluoromethylbenzoyl chloride, 3,4-dichlorobenzoyl chloride, 3,4-dimethylbenzoyl chloride, and 4-carboxybenzoyl chloride there are obtained 3,4,5-trimethoxybenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, 4-flurorobenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, 3-trifluoromethylbenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, ~0 3,4-dichlorobenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, 3,4-dimethylbenzenecarbothioic acid, 2-aminoethyl ester hydrochloride, and 4-carboxybenzenecarbothioic acid, 2-aminoethyl ester hydrochloride.
Example~6 ~ hen in the procedure of Example 1, 2-aminoethanethiol ~.~,3~f~7~3 hydrochloride is replaced by equal molar amounts of 3-amino-propanethiol hydrochloride, there is obtained benzenecarbothioic acid-3-aminopropylester hydrochloride.
Example 7 When in the procedure of Example 1, 2-aminoethanethiol h~drochloride is replaced by equal molar amounts of 3~amino-propanethiol hydrochloride and benzoyl chloride is replaced by p-chlorobenzoyl chloride, p-toluoyl chloride, or p-anisoyl chloride there are obtained 4-chlorobenzenecarbothioic acid, 3-aminopropyl ester hydrochloride, 4-methylbenzenecarbothioic acid, 3-aminopropyl ester hydrochloride, and 4-methoxybenzenecarbothioic acid, 3-aminopropyl ester hydrochloride.
Example 8 2-Thiophenecarbothioic Acid, 2-Aminoethyl Ester, 2a Hydrochloride.
A mixture of freshly distilled 2-thiophenecarbonyl chloride, 15.8 g. (0.108 mole) and 2-aminoethanethiol hydrochloride 11.3 g. (0.1 mole) was heated (protected from mois~ure) over a steam jet for 6 hours. The resulting solid crystalline mass was crushed and triturated with warm 60-110C. ligroine and filtered to collect the crystals. After two recrystallizations from anh~drous ethanol, the product, 8.41 g. (75.5%) melted at 195-196.5C. NMR, MS and IR all supported the structure of the title compound in accordance with Formula I.
Analysis: Calculated for C7HloClNOS2: C,37.58; H,4.51; N,6.26 Found : C,37.68; H,4.50; N,6.30 Example 9 When in the procedure of Example 8, 2-aminoethanethiol hydrochloride is replaced by equal molar amounts of 3-amino propanethiol hydrochloride, there is obtained thiophenecarbothioic acid, 3-aminopropyl ester hydrochloride.
The pharmaceutical compositions of this invention comprise benzenecarbothioic aoid, 2-aminoethyl ester acid salts in an amount sufficient to provide efective action against lung congestion in warm-blooded animal subjects when applied topically as an inhalant.
The compounds of Formula I are administered in an amount sufficient to induce liquefaction of mucus in the respiratory tract o warm-blooded animals in need thereo. Intratracheal administration of the compounds of Formula I is effected by various inhalation or instillation means such as nose drops, sprays, aerosols and the like. Another suitable means of administration ~0 is by insufflation of micronized particle or ultra-fine powder utilizing only the energy of the inspiratory action or by use of aerosol propellants. Solutions or suspensions having about 0.5 to 5% weight of the mucolytic agent of Formula I are suitable for application by spraying with an atomizer, nebulizer, aerosol and the like.
~ t will be readily apparent to those skilled in the medical art that the correct dosage of a compound to be employed -- 11 -- ..
7~
with any particular ma~malian subject is determined by the severity of the condition requiring mucolytic therapy, as well as the age, sex, weight and general physical condition o the sub~ect.
Individual doses ranging from 5-100 mg. for inhalation by man are suitable and may be required for the mucolytic effect.
The pharmaceutical compositons may take the form of dilutions of the micronized compounds in dusts or solutions and suspensions in liquids suitably dispensed for inhalation as illustrated following.
A. Powder for Administration via In,haler Device.
4-Chlorobenzenecarbothioic acid, 2-aminoethyl ester monohydrochloride of Example 2, micronized 2.5 g.
Lactose powder 2.5 g, The powders are blended aseptically and filled into hard gelatin capsules each containing 50 mg. of the mixture.
This is suitable for dispersion into the inspired breath by means o~ a breath-operated inhaler device containing means for rupture of the capsule wall prior to dosing.
~0 B. Sterile Solution for Administration via Inhaler Device.
1. Active Ingredients 100 mg.
2. Alcohol 95%, q.s. 1.0 cc.
Dissolve No. 1 and 2 by warming and administer by means of breath-operated inhaler device.
~3~27~3 C. Aqueous Solution 1. Active Ingredient, Ex. 1, 3 or 5 10 g.
2. Distilled water 90 Total 100 g.
Dissolve 1 in 2 and dilute to dosage forms and administer by means of inhaler device or aerosol.
~: .
:
: - 13 - ~ ' '~
- ., . .: .; : ' ' ,: . ' :. : :,.,: : :: , . ., : . ~ : :~ ' . . ' ' .: ' . ' ,::, : '-.
. . , ' - . ': .. . '''., `.. ., ' . '.. ' . : .' .
with any particular ma~malian subject is determined by the severity of the condition requiring mucolytic therapy, as well as the age, sex, weight and general physical condition o the sub~ect.
Individual doses ranging from 5-100 mg. for inhalation by man are suitable and may be required for the mucolytic effect.
The pharmaceutical compositons may take the form of dilutions of the micronized compounds in dusts or solutions and suspensions in liquids suitably dispensed for inhalation as illustrated following.
A. Powder for Administration via In,haler Device.
4-Chlorobenzenecarbothioic acid, 2-aminoethyl ester monohydrochloride of Example 2, micronized 2.5 g.
Lactose powder 2.5 g, The powders are blended aseptically and filled into hard gelatin capsules each containing 50 mg. of the mixture.
This is suitable for dispersion into the inspired breath by means o~ a breath-operated inhaler device containing means for rupture of the capsule wall prior to dosing.
~0 B. Sterile Solution for Administration via Inhaler Device.
1. Active Ingredients 100 mg.
2. Alcohol 95%, q.s. 1.0 cc.
Dissolve No. 1 and 2 by warming and administer by means of breath-operated inhaler device.
~3~27~3 C. Aqueous Solution 1. Active Ingredient, Ex. 1, 3 or 5 10 g.
2. Distilled water 90 Total 100 g.
Dissolve 1 in 2 and dilute to dosage forms and administer by means of inhaler device or aerosol.
~: .
:
: - 13 - ~ ' '~
- ., . .: .; : ' ' ,: . ' :. : :,.,: : :: , . ., : . ~ : :~ ' . . ' ' .: ' . ' ,::, : '-.
. . , ' - . ': .. . '''., `.. ., ' . '.. ' . : .' .
Claims
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A pharmaceutical composition useful as a mucolytic agent in an animal body suffering from lung congestion which comprises a pharmaceutically active amount of a compound of the formula X-wherein; R is benzene, X- is chlorine or bromine radical, and n is 2 or 3, which is in admixture with a pharmaceutically acceptable diluent or carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA396,307A CA1134273A (en) | 1978-08-10 | 1982-02-15 | Benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93274778A | 1978-08-10 | 1978-08-10 | |
| US932,747 | 1978-08-10 | ||
| CA333,424A CA1125297A (en) | 1978-08-10 | 1979-08-09 | Benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts |
| CA396,307A CA1134273A (en) | 1978-08-10 | 1982-02-15 | Benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1134273A true CA1134273A (en) | 1982-10-26 |
Family
ID=27166355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA396,307A Expired CA1134273A (en) | 1978-08-10 | 1982-02-15 | Benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1134273A (en) |
-
1982
- 1982-02-15 CA CA396,307A patent/CA1134273A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3027075A1 (en) | BENZISOSELENAZOLONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| PL154186B1 (en) | Method for manufacturing arylic derivatives of the hydroxamic acid | |
| US4857301A (en) | Sulfonamide compounds, compositions and method of use | |
| JPH0324052A (en) | Halogen-substituted diphenyl- sulfide, its manufacture, and drug containing said sulfide | |
| JPS609716B2 (en) | 1,2-Benzinthiazolin-3-ones, their production method and use as medicine | |
| KR100526093B1 (en) | Method and compound for treating protozoal infections | |
| KR100979077B1 (en) | Solid salts benzazepine compounds and pharmaceutical compositions comprising them | |
| CA1134273A (en) | Benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts | |
| JPH0153266B2 (en) | ||
| US4210666A (en) | Mucolytic thiophenecarboxamido alkyl mercaptans | |
| DE2360193A1 (en) | CYAN-SUBSTITUTED N, N '- (PHENYLEN) -DIOXAMIC ACIDS AND THEIR SALTS, PROCESS FOR THEIR PRODUCTION AND THERAPEUTIC AGENTS CONTAINING THE SAME | |
| JPS5829782A (en) | Novel heterocyclic compound, its preparation and medicinal composition containing said compound | |
| US4296092A (en) | Mucolytic benzene and thiophene-carbothioic acid 2-aminoalkyl ester acid salts | |
| IE48794B1 (en) | Benzene and thiophene-carbothioic acid 2 aminoalkyl ester acid salts | |
| EP0037187B1 (en) | Salts and aqueous solutions of 6-methylamino-4-oxo-10-propyl-4h-pyrano(3,2-g)-quinoline-2,8-di-carboxylic acid and pharmaceutical compositions containing such salts and solutions | |
| CA1129881A (en) | Benzamidoalkyl mercaptans | |
| EP0045473B1 (en) | A pharmaceutical composition containing a benzofuran-carboxamide derivative as the active ingredient | |
| US4472424A (en) | Esters of 2-thenoylmercaptopropionylglycine with substituted hydroxybenzenes, process for their preparation and pharmaceutical compositions containing same | |
| JPS6361311B2 (en) | ||
| JPS5910563A (en) | Alpha-(n-pyrrolyl)-phenylacetic acid derivative and manufacture | |
| SU1711673A3 (en) | Method for the synthesis of ethanolamine or theirs physiologically acceptable salts or solvates | |
| JPS5942377A (en) | Dithiol derivative | |
| JPH03184967A (en) | Furosemide salt, its preparation, use thereof as drug and pharmaceutical composition containing same | |
| JPS59148778A (en) | 1,3-dithiethane derivative and its use | |
| JPH0439470B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |